[Congenital toxoplasmosis due to maternal reinfection during pregnancy]. / Toxoplasmose congénitale secondaire à une réinfection maternelle pendant la grossesse.

Reinfection with Toxoplasma gondii is exceptional but can lead to transmission to the fetus when it occurs during pregnancy. We present a case of congenital toxoplasmosis in a young baby born to an immunocompetent mother who had been immunized against toxoplasmosis before pregnancy. The presence of residual IgG-specific antibodies does not always mean an absolute protection against a new toxoplasma infection. During the pregnancy, the patient was advised to follow the hygienic and dietary preventive measures even though the previous test results were consistent with past toxoplasma infection.

[Difficulties of interpretation in toxoplasma serology in a pregnant woman in the context of a maternofetal alloimmunization against HPA-1a platelet antigen]. / A propos d'un cas de sérologie toxoplasmique chez une patiente enceinte dans un contexte d'allo-immunisation foetomaternelle anti-HPA-1a.

Serological status in case of Toxoplasma gondii infection needs to be established either before or at the beginning of a pregnancy. However, clinical biologists are often facing conflicting serological results that are difficult to interpret: we report here the case of a woman in her 30th week of pregnancy. Both her IgM and IgG were negative at the 14th week of pregnancy; but suddenly, starting from the 20th week, her IgG became positive while her IgM remained negative. We remind here of the most frequent hypothesis that can explain a sudden and isolated increase of anti-T. gondii IgG: Is it a technical problem (specificity)? Is it a drug interference? Eventually, we found that the patient was receiving, since the 16th week of pregnancy, every week an intravenous perfusion of polyvalent immunoglobulins. Since we didn't know if the IgG present in this perfusion can protect the patient against toxoplasmosis, we decided to consider this women as non immune.

Severe side effects and drug plasma concentrations in preterm infants treated with doxapram.

A high-performance liquid chromatography method has been developed for simultaneous determination of doxapram and its metabolites including ketodoxapram, the main and only active metabolite. The aim of the study was to evaluate this microtechnique and to report the cases involving severe adverse effects to determine toxic plasma levels in neonates. The method was found to be selective, and showed a good baseline separation of doxapram and metabolites. Recovery, linearity, intraday/interday precision, and limit of detection determined in aqueous solutions and in spiked plasma were satisfactory. The assay is simple, rapid, and plasma-sparing, which represents a true advantage in managing neonates. Case analysis was performed in two consecutive periods: 124 preterm infants in the first period and 173 in the second period. Severe toxic effects were observed in 4 cases in the first period, with doxapram plus keto-doxapram levels 9 mg/L. In the second period, only one case was observed. High-range plasma concentrations were significantly less frequent in the second period than in the first one. The authors conclude that measuring doxapram plus keto-doxapram in plasma may be of interest to avoid severe toxic effects in preterm neonates treated with doxapram.

Undetectable luteinizing hormone levels using a monoclonal immunometric assay.

Previous studies have shown wide discrepancies among the results obtained with different immunometric assays. We present five cases (out of 4000 women) whose plasma luteinizing hormone was not detected using a LH immunometric assay (LH Stratus Baxter) but was recognized by other kits. These cases concerned one 28-year-old woman presenting with infertility and four postmenopausal women. The LH Amerlite kit gave detectable but low results. The results obtained with the other kits were > 7 IU/l. FSH levels were > 7 IU/l. In one case, sera were taken before and after the menopause; differences between the LH results increased. Discrepancies among LH assay kits have been attributed to variation both in standard curve calibration and in epitope specificity of the kit monoclonal antibodies. The Baxter kit might misrecognize some isoforms present in postmenopausal women. The present data illustrate the potential false results with such immunoassays in routine clinical laboratory testing. When undetectable LH results are not clinically explained or when disparities between LH and FSH are observed, we suggest using a second methodology or a bioassay if necessary. Improvement in LH assays and standardization might resolve the problem of discrepancies between the LH results.

Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta-subunit.

OBJECTIVE: The purpose of the study was to evaluate plasma inhibin as a marker of hydatidiform mole and to compare the results with intact human chorionic gonadotrophin (hCG) and its free beta-subunit. DESIGN: Serial determinations of the plasma concentrations of inhibin, intact human chorionic gonadotrophin and its free beta-subunit in cases of hydatidiform mole over an average period of 140 days. PATIENTS: Five cases of hydatidiform mole, including patients with spontaneous remission after evacuation or persistent trophoblastic disease. MEASUREMENTS: Immunoreactive inhibin, hCG and free hCG beta-subunit were measured using standard enzyme immunoassays. RESULTS: Inhibin and free hCG beta-subunit levels were greater than in normal pregnant women at the same gestational age. Only intact hCG could detect the persistence of trophoblastic tissue. CONCLUSIONS: Our data suggest that inhibin, intact human chorionic gonadotrophin and free beta-subunit might be useful as diagnostic markers of molar pregnancies. However, the original method of intact hCG determination is still superior for follow-up.